Analyst Andrew Fein from H.C. Wainwright maintained a Buy rating on MetaVia and keeping the price target at $20.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Andrew Fein’s rating is based on the view that DA-1726 has credible potential to distinguish itself in an increasingly crowded GLP-1 market, particularly through its apparent ability to drive sustained weight loss and meaningful reductions in waist circumference over time. He emphasizes that the glucagon component could be enabling deeper visceral and central fat reduction than selective GLP-1 agonists, which, if confirmed at higher doses and longer durations, would provide a mechanistically sound edge.
He also points to upcoming ADA and EASL presentations as important catalysts that could validate DA-1726’s safety, tolerability, pharmacokinetic, and hepatic profiles, thereby de-risking the pivotal 4Q26 data readout and reinforcing its potential role in liver-focused combination regimens and MASH. In addition, preclinical vanoglipel combination data in metabolic and liver indications may further support a differentiated, combination-driven strategy, justifying a continued Buy rating and an unchanged $20 price target for MetaVia (MTVA).